Search research articles
Contact Us
Filters
Showing results (51-60 of 76) with videos related to
Page
of 8
Sort By:
British Journal of Cancer
|
February 27, 2015
Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents
M Crespo, G van Dalum, R Ferraldeschi, et al.
British Journal of Cancer
|
July 3, 2008
Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer
G Attard, J Clark, L Ambroisine, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 1, 2021
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial
A Jayaram, A Wingate, D Wetterskog, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 25, 2014
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer
R Leibowitz-Amit, A J Templeton, A Omlin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 15, 2021
Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial
A A Hamid, H-C Huang, V Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 13, 2008
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience
D Olmos, H-T Arkenau, J E Ang, et al.
Research Involvement and Engagement
|
November 18, 2021
ReIMAGINE: a prostate cancer research consortium with added value through its patient and public involvement and engagement
S Green, S Tuck, J Long, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2022
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
J Pascual, G Attard, F-C Bidard, et al.
British Journal of Cancer
|
January 28, 2010
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer
A H M Reid, G Attard, L Ambroisine, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 18, 2025
Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase III trials of docetaxel and zoledronic acid using healthcare systems data
C Jones, P Dutey-Magni, L R Murphy, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 76) with videos related to
Sort By:
Page
of 8
British Journal of Cancer
|
February 27, 2015
Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents
M Crespo, G van Dalum, R Ferraldeschi, et al.
British Journal of Cancer
|
July 3, 2008
Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer
G Attard, J Clark, L Ambroisine, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 1, 2021
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial
A Jayaram, A Wingate, D Wetterskog, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 25, 2014
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer
R Leibowitz-Amit, A J Templeton, A Omlin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 15, 2021
Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial
A A Hamid, H-C Huang, V Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 13, 2008
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience
D Olmos, H-T Arkenau, J E Ang, et al.
Research Involvement and Engagement
|
November 18, 2021
ReIMAGINE: a prostate cancer research consortium with added value through its patient and public involvement and engagement
S Green, S Tuck, J Long, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2022
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
J Pascual, G Attard, F-C Bidard, et al.
British Journal of Cancer
|
January 28, 2010
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer
A H M Reid, G Attard, L Ambroisine, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 18, 2025
Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase III trials of docetaxel and zoledronic acid using healthcare systems data
C Jones, P Dutey-Magni, L R Murphy, et al.
Page
of 8